Click on the "Follow" button below and you'll get the latest news from Healthcare Communications Network via email, mobile or you can read them on your personal news page on this site.
You can unsubscribe anytime you want easily.
You can also choose the topics or keywords that you're interested in, so you receive only what you want.
Healthcare Communications Network title: Connecting Healthcare - Healthcare Communications Network
Is this your feed? Claim it!
Evidence Review
Researchers reviewed longitudinal MRI studies evaluating brain changes before and after CPAP therapy in adults with OSA. While multiple studies reported imaging changes following treatment, findings varied substantially across MRI modalities, brain regions studied, CPAP adherence definitions, and analytic approaches.
Clin...Clinical Decision Support / Validated Tool
Researchers evaluated a whole-blood point-of-care GFAP/UCH-L1 assay in adults presenting within 24 hours of suspected mild TBI (GCS 13-15). The study assessed whether biomarker testing could accurately identify patients unlikely to have intracranial injury on CT.
Clinical ConsiderationsClinical Decision Support / Practice Guidance
Most headache presentations do not require neuroimaging. The decision to obtain MRI, and whether to add contrast, should be driven by clinical features suggesting a secondary headache disorder. The authors provide a case-based framework for identifying situations in which MRI with and without co...
Educational / Awareness Content
Developmental topographical disorientation (DTD) is a lifelong navigation disorder that occurs without an acquired brain injury or other neurologic condition explaining the deficit. Individuals may recognize familiar landmarks but struggle to understand how locations relate to one another spatially. Severe cases can ...
Early-Stage Clinical Evidence
Researchers tested an autologous cell therapy designed to restore immune tolerance to myelin by attaching myelin peptides to a patient’s own red blood cells before reinfusion. In a Phase 1b study involving 10 people with MS, the therapy was generally well tolerated and produced immune changes consistent with increased ...